Regado Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry...

Regado Biosciences to Present at the 16th Annual Future Leaders in the Biotech
Industry Conference

BASKING RIDGE, N.J., March 30 /PRNewswire/ -- Regado Biosciences today
announced that the Company's Chief Executive Officer, David J. Mazzo, Ph.D.,
will be presenting at the upcoming 16th Annual Future Leaders in the Biotech
Industry Conference to be held at the Millennium Broadway Hotel and Conference
Center in New York City. Dr. Mazzo's presentation is scheduled to begin on
Thursday, April 2, 2009 at 3:00 PM (EDT). A copy of Dr. Mazzo's presentation
will also be available on the Company's website beginning on April 3, 2009.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the
creation and development of two-component drug systems. Each system is
comprised of an aptamer therapeutic that can be controlled directly by its
specific and matched active control agent. This technology is being applied to
acute care injectable antithrombotics, a multi-billion dollar market in need
of therapeutics with improved safety profiles and a greater degree of
therapeutic control. Regado's technology is designed to give physicians the
ability to actively and directly control each system's therapeutic effect
providing a safe and unique approach to personalized medicine.

Regado's lead program, REG1, is comprised of two parenteral agents, the first
being a potent and highly selective Factor IXa inhibitor (RB006) and the
second being its complementary active control agent (RB007), which can be used
to completely or selectively lower the anticoagulant effect. Regado recently
completed a phase 2a study of REG1 in percutaneous coronary intervention (PCI)
and is planning the initiation of a rigorous phase 2b program in that same
indication in 3Q2009.

SOURCE Regado Biosciences, Inc.

Ellen McDonald, Chief Business Officer for Regado Biosciences,
+1-908-580-2113, emcdonald@regadobio.com